Jason Camm is Founder, President, and Chief Executive Officer of Beren Therapeutics P.B.C., a global, fully integrated biotechnology company developing first-in-class cyclodextrin-based medicines.

Founded in 2020, Beren is among the first biotechnology companies established as a Public Benefit Corporation, reflecting its commitment to long-term innovation and measurable societal impact. Under Jason’s leadership, Beren has built a fully integrated organization spanning discovery through commercialization, staffed by executives and scientists who have contributed to more than 46 FDA drug approvals.

Jason served as Founder and General Partner of Thiel Bio Fund, LP and Managing Director and Chief Medical Officer of Thiel Capital LLC, where he directed global biotechnology investments.

His investments include AbCellera (ABCL), COMPASS Pathways (CMPS), New Amsterdam Pharma (NAMS), Kite Pharma (acquired by Gilead Sciences), Juno Therapeutics (acquired by Celgene), DiCE Molecules (acquired by Eli Lilly), Alloy Therapeutics, Cleerly, Peptilogics, and Histosonics. Jason has held board seats across much of the portfolio.

Jason was named a Young Global Leader of the World Economic Forum and has contributed board service to non-profit organizations, including the Thiel Foundation and the Friedman School of Nutrition Science and Policy at Tufts University.

Originally from the United Kingdom, Jason resides in Los Angeles with his wife and three children.

Aaron Ondrey joined Beren Therapeutics P.B.C. as Chief Financial Officer in September 2025. He is a finance executive with over 25 years of experience in strategic financial management, capital allocation, and investor relations across public and private organizations.

Aaron has held senior finance positions at Vertex, Alexion, and Regeneron where he supported the company’s rapid expansion and a more than 20x growth multiple starting in 2010.

Over his career, he has overseen more than $10 billion in strategic transactions, including the $5 billion acquisition of Mirati Therapeutics by Bristol Myers Squibb, where he served as CFO, and the $6.7 billion acquisition of Arena Pharmaceuticals by Pfizer. Aaron also served as CFO of Rocket Pharmaceuticals.  

Aaron holds a B.S. from Case Western Reserve University. In his spare time, he enjoys the coast of Maine with his wife, three children, and two dogs.

Dr. Alex Gold, MD is Chief Medical Officer at Beren Therapeutics P.B.C., with 25 years of biopharmaceutical experience spanning global clinical development, regulatory strategy, and commercialization. He has led programs resulting in five globally approved products and played key roles in multiple company acquisitions.

Previously, Dr. Gold was President and Chief Medical Officer of Sanifit Therapeutics, leading the company through its acquisition by Vifor Pharma. He also served as SVP and Head of Clinical Development and Medical Affairs at Portola Pharmaceuticals, where he led regulatory approvals for BEVYXXA® and ANDEXXA®, and held earlier leadership roles at Reata Pharmaceuticals and AstraZeneca, contributing to the development of CRESTOR®, ONGLYZA®, and BRILINTA®.

Dr. Gold serves as an independent director at Mineralys Therapeutics and VarmX and is an Adjunct Professor at Stanford University School of Medicine. He earned his MD from Harvard Medical School and completed his postgraduate training at Beth Israel Deaconess Medical Center.

Jennifer “Jen” Spinella, MT(ASCP), RAC is Chief Regulatory Officer and Head of Quality at Beren Therapeutics, PBC, where she leads global regulatory strategy, quality systems, and health authority engagement across neurology, cardiovascular, and rare disease programs. She brings more than 30 years of regulatory and quality leadership experience spanning drugs, biologics, gene therapies, devices, and diagnostics, and has supported multiple U.S. and global drug approvals, including first‑in‑class and rare therapies such as RITUXAN®, CARBAGLU®, CYSTADANE®, ORFADIN®, ANASCORP®, ANAVIP®, and PURIXAN®.  

Prior to Beren, she held senior regulatory leadership roles at Gossamer Bio, Biogen, Chugai, Renova Therapeutics, and Rare Disease Therapeutics, with deep expertise in expedited development pathways and complex approval strategies.  

Jen holds a B.S. in Medical Technology and is board certified as a Medical Technologist and Regulatory Affairs Certified professional.

Dr. Irene von Hennigs, PharmD, brings more than 30 years of biopharma experience to her role as SVP, Global Medical Affairs at Beren Therapeutics P.B.C. She has led the development of medical affairs functions and integrated strategies spanning evidence generation, scientific communications, and stakeholder engagement.

Dr. von Hennigs’s rare disease experience began at AbbVie where she supported CREON® for cystic fibrosis, including its landmark FDA approval in 2009. She has since led Medical Affairs at Alexion across SOLIRIS® and ULTOMIRIS® in ultra-rare hematologic, renal, and neurological diseases. Her portfolio at Amgen spanned the Rare Disease Business Unit across both rare and ultra-rare disease, including PROCYSBI® for the treatment of a rare, life-threatening metabolic lysosomal storage disorder typically diagnosed in infancy. Irene brings the full breadth of that experience to Beren, where she now focuses on Niemann-Pick disease, type C.

Dr. von Hennigs is recognized for her strategic and entrepreneurial mindset, with a disciplined approach to portfolio prioritization and cross-functional execution. She holds a PharmD from Mercer University and completed a pharmacy practice residency at The Johns Hopkins Hospital.  

Bennett Smith is Senior Vice President, Commercial at Beren Therapeutics P.B.C., where he leads the global commercial organization and commercial strategy for Beren's first product launch in infantile-onset Niemann-Pick disease, type C (I-NPC).  

With more than two decades of pharmaceutical and biotech leadership, Bennett joined Beren after serving as Senior Vice President and General Manager, North America at Orchard Therapeutics, where he led the North American commercialization and launch of LENMELDY®, a first-in-class cell and gene therapy for metachromatic leukodystrophy (MLD), an ultra-rare pediatric neurodegenerative disease.  

He previously held senior commercial and market access leadership roles at Akebia Therapeutics, Regeneron, Novo Nordisk, and Forest Laboratories, leading strategy across nephrology with VAFSEO® and AURYXIA®, cardiovascular and rare disease with PRALUENT® and EVKEEZA® (the latter for homozygous familial hypercholesterolemia, a rare genetic disease), the GLP-1 franchise with VICTOZA®, SAXENDA®, and TRESIBA®, and anti-infectives with TEFLARO®.  

Bennett holds an MBA from the University of Washington and a BA in Biology from the College of Idaho, where he graduated cum laude.

Cathy is a skilled advocacy leader with over 20 years of US and Global experience in pharmaceutical, policy, and healthcare advocacy organizations. She has developed and implemented international and transformational initiatives, engaging key stakeholders across therapeutic areas and from industry, advocacy, and policy perspectives.

She has worked across multiple cultures and countries throughout her career, utilizing optimism and strong personal beliefs to overcome social and business challenges and mobilize people around a higher purpose. Cathy is driven by integrity and strong ethical principles and committed to corporate patient responsibility. She has broad advocacy experience gained through leadership roles at Bristol Myers Squibb, Endo Pharmaceuticals, and GlaxoSmithKline. She also gained first-hand experience in health policy and patient advocacy working for NJ Governor Christine Todd Whitman and The Leukemia & Lymphoma Society, respectively.

She is a recognized expert in relationship building, influential initiatives, strategic industry alliances, and global partnerships. Cathy holds a BA in Political Science & Health Policy and earned a Harvard Kennedy School Certification in Creating Collaborative Solutions.

Rajinder “Raj” Singh, Ph.D., serves as Chief Scientific Officer at Beren Therapeutics P.B.C., where he leads the company's scientific strategy and advancement of innovative therapies for diseases with high unmet need. Raj brings more than three decades of experience in pharmaceutical research and development, with deep expertise spanning organic chemistry, drug discovery, and translational development.

Prior to joining Beren, Raj held senior leadership roles across multiple biotechnology organizations, including Chief Scientific Officer at Circle Pharma, Senior Vice President of Research & Pharmaceutics at ChemoCentryx, and Vice President of Chemistry at Rigel Pharmaceuticals. In these roles, he led multidisciplinary teams from early discovery through clinical development, regulatory submission, and approval, translating scientific innovation into clinically impactful medicines for underserved patient populations.  

Raj has played a direct, decision-making role across 16 IND candidates and more than 15 Phase 2 and 10 Phase 3 clinical studies, including the development and approval of TAVALISSE® and TAVNEOS®, both first-in-class therapies for rare, systemic immune-mediated diseases.

Raj received his D.Phil. in organic chemistry from the University of Oxford and his BSc from Cardiff University.

Magali Hickey, Ph.D. serves as SVP, Technical Operations and CMC at Beren Therapeutics P.B.C. and is a pharmaceutical and biotech executive with over 25 years of experience advancing innovative therapies. She has contributed to the development and commercialization of multiple products, including ZEFTERA®, VIVITROL®, ARISTADA®, ARISTADA INITIO®, VUMERITY®, and LYBALVI®. Her expertise spans small molecules, biologics, peptides, lipid nanoparticles, mRNA, and drug-device combinations, with a focus on drug delivery and precision medicine.

Magali has authored 150+ peer-reviewed publications, patents, and presentations. Her regulatory experience includes oversight of CMC strategies for dozens of global submissions across CNS, metabolic disease, oncology, and vaccines. She has held senior leadership roles at Moderna, Lyndra Therapeutics, Alkermes, Syntis Bio, Johnson & Johnson, and TransForm Pharmaceuticals.

Passionate about diversity, patient focus, and team culture, Magali also serves on scientific advisory boards and leadership councils driving global health impact. She earned her Ph.D. in Organic Chemistry from Brandeis University and her B.S. in Chemistry from UMass Boston.

Heather McCuen is the Chief People Officer at Beren Therapeutics P.B.C. She is a People & Culture leader with over two decades of experience across People strategy, operational excellence, and infrastructure for high-growth startups.

Prior to Beren, Heather was Global Head of Human Resources for Atoms (formerly Cloudkitchens), and previously Head of Global Policy on the People team at WeWork after opening the first WeWork in Canada in 2016. She has grown and scaled the People infrastructure of early-stage startups across over 40 countries and spent several years as a visiting professor of Social Innovation for the UN-mandated University for Peace's Center for Executive Education.

Heather earned her master's degree in Media, Peace and Conflict Studies from the University for Peace and is a graduate of Harvard University's National Preparedness Leadership Initiative. In her spare time, she volunteers for emergency response organizations to deepen her expertise in crisis stewardship and community building.

Peter “Pete” Cicala, JD serves as Beren’s General Counsel and Head of Intellectual Property and Innovation. Pete brings more than 30 years of pharmaceutical experience in drug development, intellectual property, and general commercial law. He has particular expertise in strategic management of IP assets, M&A, research collaborations, and patent enforcement litigation in major pharmaceutical markets.  

Prior to Beren, Pete served as Chief Patent Counsel at Celgene where he managed a portfolio of over 25,000 patents, including all IP for the IMiDs franchise that included REVLIMID, THALOMID, and OTEZLA. He also handled all business development contracts, enforced all patents globally, and managed M&A transactions – including the ~$80B acquisition of Celgene by BMS.  

Pete also served as VP of IP at Shire, where he managed the entire portfolio and all patent litigation. He has been responsible for the IP portfolios for over 25 approved therapies during his career. Pete is the co-founder of Pretzel Therapeutics and other private start-up biotechnology companies, and he sits on the Board of Directors of Ernexa Therapeutics.  

Pete is a medicinal chemist and worked within Merck’s Chemistry Department for several years in drug discovery and process research prior to receiving his legal training.

Pete earned his JD from Seton Hall School of Law and a B.S. in Chemistry from Fairleigh Dickinson University.